- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.02. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | iSpecimen Inc.: iSpecimen Secures Suppliers for COVID-style hMPV Outbreak | 383 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus... ► Artikel lesen | |
| 16.01. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.12.24 | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 20.12.24 | iSpecimen expands cancer biospecimen services for research | 3 | Investing.com | ||
| 20.12.24 | iSpecimen Inc.: iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens | 321 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025... ► Artikel lesen | |
| 13.12.24 | iSpecimen Up on Positive Results From NDQ | 2 | Baystreet.ca | ||
| 13.12.24 | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | 848 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| 13.12.24 | iSpecimen Inc.: iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers | 288 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen appoints Robert Lim as CEO | 1 | Seeking Alpha | ||
| 12.12.24 | iSpecimen Inc.: iSpecimen Appoints Robert Lim as CEO and Director | 491 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11.24 | iSpecimen Inc.: iSpecimen Named Top Competitor in $4.4 Billion USD Market | 280 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 07.11.24 | iSpecimen Inc: iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually | 2 | GlobeNewswire (USA) | ||
| 07.11.24 | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 31.10.24 | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.10.24 | iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 30.10.24 | iSpecimen sets $5 million public stock offering at $3 per share | 2 | Investing.com |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 80,22 | -6,16 % | Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today | ||
| CRISPR THERAPEUTICS | 40,400 | -5,16 % | Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why | ||
| INTELLIA THERAPEUTICS | 9,080 | -6,60 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress | Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics... ► Artikel lesen | |
| EDITAS MEDICINE | 1,731 | -6,20 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 110,00 | -3,89 % | Neurocrine's Phase 4 Study Shows INGREZZA Improves Quality Of Life For Tardive Dyskinesia Patients | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained effects of INGREZZA (valbenazine)... ► Artikel lesen | |
| BLUEBIRD BIO | 3,660 | -6,63 % | bluebird bio stock slides for second day on buyout news | ||
| ARROWHEAD PHARMACEUTICALS | 16,940 | -7,10 % | Arrowhead, Zevra fire up campaigns for Rare Disease Day 2025 | ||
| GALAPAGOS NV | 24,800 | -1,20 % | Galapagos NV: Galapagos to Present at Upcoming Investor Conferences | Mechelen, Belgium; February 24, 2025, 22:01 CET - Galapagos NVBarclays 27th Annual Global Healthcare ConferenceDate: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,800 | -7,20 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update | - Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer ("mCRC") clinical trial (CRDF-004) - - Priced oversubscribed $40 million... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,590 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| TWIST BIOSCIENCE | 35,410 | -5,35 % | Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday | ||
| REPLIGEN | 152,30 | -0,85 % | TD Cowen raises DHR, TMO, AVTR, RGEN stock ratings on growth outlook | ||
| ROCKET PHARMACEUTICALS | 9,034 | -0,77 % | Scotiabank Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock | ||
| XBIOTECH | 3,460 | +1,76 % | XFRA 4XB: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PERSONALIS | 3,888 | -2,70 % | Personalis stock target cut to $7 by BTIG, maintains Buy rating |
ISPECIMEN INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.
